Mitoconix Bio
Therapeutics for Neurodegenerative Diseases
Company Overview
Snapshot
Founded in June 2016 by Daria Mochly-Rosen, Mitoconix Bio operates with 1–10 employees. The company has secured $20M in total capital across two funding rounds from six investors. In June 2017, the company raised an A Round with participation from RMGP Biopharma Investment Fund.
Business overview
Mitoconix Bio is a Health Tech & Life Sciences company focused on developing disease-modifying therapeutics for neurodegenerative diseases. The company's core technology involves a strategy for improving mitochondrial health, with its lead drug being an inhibitor of pathological mitochondrial fragmentation and dysfunction. This drug has demonstrated in vivo efficacy in animal models of Huntington's and Parkinson's disease, and beneficial activity in patient-derived cells for Huntington's, sporadic and genetic Parkinson's, and sporadic and genetic Alzheimer's disease. Mitoconix Bio operates in the Pharmaceuticals sector, serving global markets with a B2B business model.
Strategic signal
In July 2019, Mitoconix Bio ceased operations, indicating a significant shift in its corporate trajectory. This event signals to investors and innovation teams that the company is no longer actively pursuing its therapeutic development, marking a critical inflection point in its history.
Company Intelligence Q&A
- What is Mitoconix Bio's primary focus?
- Mitoconix Bio is focused on developing disease-modifying therapeutics for neurodegenerative diseases, utilizing a strategy to improve mitochondrial health.
- When was Mitoconix Bio founded?
- Mitoconix Bio was founded in June 2016.
- What was a key funding event for Mitoconix Bio?
- In June 2017, Mitoconix Bio raised an A Round of funding with participation from.
- What is the status of Mitoconix Bio?
- Mitoconix Bio is currently non-active, having ceased to operate in July 2019.
- Which diseases does Mitoconix Bio's lead drug target?
- Mitoconix Bio's lead drug has shown efficacy in animal models of Huntington's disease and Parkinson's disease, and beneficial activity in patient-derived cells for Huntington's, sporadic and genetic Parkinson's, and sporadic and genetic Alzheimer's disease.